NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
Clinical Trials
17 trialsNCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02384759 2024-07-10
FOLFA
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03530267 2024-02-23
ELDERLY
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03279289 2023-04-13
AFEMA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT02181556 2021-06-07
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04810585 2021-03-23
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
Yonsei University
Phase 4 Unknown
NCT04397601 2020-05-21
ARBITRATION
National Cancer Institute, Naples
Unknown
NCT01669720 2020-02-17
C261
Brown University
Phase 2 Terminated
NCT02331927 2019-09-20
PERMAD
University of Ulm
Phase 2 Unknown
NCT02624726 2019-02-22
MINOAS
Hellenic Oncology Research Group
Phase 2 Unknown
NCT01661972 2018-10-29
X-TRAP
Duke University
Phase 1/2 Completed
NCT01843725 2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1 Completed
NCT02129257 2017-10-24
AMALTHEA
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT03264274 2017-08-31
AUSCOR
Barts & The London NHS Trust
Phase 2 Withdrawn
NCT02079220 2017-07-31
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT02045030 2016-11-16
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Phase 2 Terminated